| abstract |
Non-peptidic compounds of formula (I) (see formula I) having activity as specific antagonists of the bradykinin B2 receptor (BK); the compounds are chemically characterized by the presence of an alpha, alpha-disubstituted amino acid, at least one free or salified amino group or the corresponding quaternary ammonium salt; These BK receptor antagonists are a novel class of medications that can be used in all disorders where the receptors are involved. |